68 related articles for article (PubMed ID: 9531302)
21. Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity.
Yang ZM; Li EM; Lai BC; Wang YL; Si LS
Biochem Cell Biol; 2007 Apr; 85(2):196-202. PubMed ID: 17534400
[TBL] [Abstract][Full Text] [Related]
22. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
23. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
24. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
[TBL] [Abstract][Full Text] [Related]
25. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
26. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.
Galea-Lauri J; Darling D; Gan SU; Krivochtchapov L; Kuiper M; Gäken J; Souberbielle B; Farzaneh F
J Immunol; 1999 Jul; 163(1):62-70. PubMed ID: 10384100
[TBL] [Abstract][Full Text] [Related]
27. Expression and characterization of glycolipid-anchored B7-1 (CD80) from baculovirus-infected insect cells: protein transfer onto tumor cells.
Nagarajan S; Selvaraj P
Protein Expr Purif; 1999 Nov; 17(2):273-81. PubMed ID: 10545276
[TBL] [Abstract][Full Text] [Related]
28. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.
Baban B; Hansen AM; Chandler PR; Manlapat A; Bingaman A; Kahler DJ; Munn DH; Mellor AL
Int Immunol; 2005 Jul; 17(7):909-19. PubMed ID: 15967784
[TBL] [Abstract][Full Text] [Related]
29. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
30. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
31. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ
Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195
[TBL] [Abstract][Full Text] [Related]
32. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
33. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
Dong H; Zhu G; Tamada K; Chen L
Nat Med; 1999 Dec; 5(12):1365-9. PubMed ID: 10581077
[TBL] [Abstract][Full Text] [Related]
34. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway.
Ou D; Wang X; Metzger DL; Ao Z; Pozzilli P; James RF; Chen L; Warnock GL
Cell Transplant; 2006; 15(5):399-410. PubMed ID: 16970282
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
36. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Dong H; Strome SE; Salomao DR; Tamura H; Hirano F; Flies DB; Roche PC; Lu J; Zhu G; Tamada K; Lennon VA; Celis E; Chen L
Nat Med; 2002 Aug; 8(8):793-800. PubMed ID: 12091876
[TBL] [Abstract][Full Text] [Related]
37. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
38. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
[TBL] [Abstract][Full Text] [Related]
39. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
40. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
